Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the most common liver cancer and one of the leading causes of cancer-related deaths in the world. Mono-immunotherapy and combination therapy with immune checkpoint inhibitors (ICIs) and multitargeted tyrosine kinase inhibitors (TKIs) or anti-vascular endothelial gro...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Xuenan, Gong, Caifeng, Zhang, Wen, Zhou, Aiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885011/
https://www.ncbi.nlm.nih.gov/pubmed/36727075
http://dx.doi.org/10.3389/fonc.2022.1091088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885011/
https://www.ncbi.nlm.nih.gov/pubmed/36727075
http://dx.doi.org/10.3389/fonc.2022.1091088

Ejemplares similares